Suppliers / Wuhan Calmland Pharmaceuticals

Wuhan Calmland Pharmaceuticals

China Updated 9 July 2026

Wuhan Calmland Pharmaceuticals is an API manufacturer based in China. It holds 7 active US drug master files and 5 valid CEPs across a filed portfolio of 8 molecules. Its most recent recorded inspection, by US FDA, closed on 12 July 2019 as VAI.

7
active US DMFs
5
valid CEPs
2
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 12 July 2019 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Wuhan, China Not on file
China, China 3012447405

What they file, and where

Molecule Regulators Docs
Docetaxel EDQM, US FDA 2
Epinastine EDQM, US FDA 2
Paclitaxel EDQM, US FDA 2
Pemetrexed US FDA 2
Pemetrexed Disodium EDQM, SFDA (Saudi Arabia) 2
Decitabine US FDA 1
Mitoxantrone EDQM 1
Tenofovir Disoproxil US FDA 1

Also appears on these molecule pages

Decitabine API Docetaxel API Paclitaxel API Pemetrexed API Pemetrexed Disodium API Tenofovir Disoproxil API

Questions about Wuhan Calmland Pharmaceuticals

Does Wuhan Calmland Pharmaceuticals hold a US DMF or a CEP?
Wuhan Calmland Pharmaceuticals holds 7 active US drug master files and 5 valid CEPs. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
Is Wuhan Calmland Pharmaceuticals FDA-registered?
One site operated by Wuhan Calmland Pharmaceuticals carries an FDA establishment identifier (FEI), which means it is registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Wuhan Calmland Pharmaceuticals's last inspection go?
The most recent inspection on record closed on 12 July 2019 as VAI (Voluntary Action Indicated: issues were found but did not warrant regulatory action). 1 inspection is on file.
Where does Wuhan Calmland Pharmaceuticals manufacture?
2 registered sites are on record, in China (Wuhan and China). Every site is listed on this page with the register it came from.
What does Wuhan Calmland Pharmaceuticals make?
8 molecules are on record against Wuhan Calmland Pharmaceuticals, including Docetaxel, Epinastine, Paclitaxel and Pemetrexed. Each links through to that molecule's full manufacturer list.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Wuhan Calmland Pharmaceuticals comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 12 July 2019.

Comparable suppliers

MSN Laboratories shares 5 molecules Hetero shares 4 molecules Dr Reddy's Laboratories shares 4 molecules ScinoPharm Taiwan shares 4 molecules Jiangsu Hansoh Pharmaceutical Group shares 3 molecules

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability